Evidence map›Paper›PMID 38177924›Full record

ArticleEMBO reports2024

The NSP3 protein of SARS-CoV-2 binds fragile X mental retardation proteins to disrupt UBAP2L interactions.

Dimitriya H Garvanska, R Elias Alvarado, Filip Oskar Mundt, Richard Lindqvist, Josephine Kerzel Duel, Fabian Coscia, Emma Nilsson, Kumari Lokugamage, Bryan A Johnson, Jessica A Plante and 14 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in EMBO reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
8.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 3 institutions in 3 countries.

Dimitriya H GarvanskaNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
R Elias AlvaradoDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-1450-4854
Filip Oskar MundtNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Richard LindqvistDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.
Josephine Kerzel DuelNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Fabian CosciaNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0002-2244-5081
Emma NilssonDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0001-8123-3292
Kumari LokugamageDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Bryan A JohnsonDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Jessica A PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Dorothea R MorrisDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Michelle N VuDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Leah K EstesDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Alyssa M McLelandDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Jordyn WalkerDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Patricia A Crocquet-ValdesDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.ORCID http://orcid.org/0000-0002-2079-0076
Blanca Lopez MendezNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.ORCID http://orcid.org/0000-0001-8541-4904
Kenneth S PlanteDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
David H WalkerDepartment of Pathology, University of Texas Medical Branch, Galveston, TX, USA.
Melanie Bianca WeisserNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Anna K ÖverbyDepartment of Clinical Microbiology, Umeå University, Umeå, Sweden.ORCID http://orcid.org/0000-0001-6553-0940
Matthias MannNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Vineet D MenacheryDepartment of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX, USA.
Jakob NilssonNovo Nordisk Foundation Center for Protein Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark. jakob.nilsson@cpr.ku.dk.ORCID http://orcid.org/0000-0003-4100-1125
The University of Texas Medical Branch at Galveston · USUniversity of Copenhagen · DKUmeå University · SE

Funding

Virology CoreU19AI171413 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI SARKO, CHRISTOPHER · 2022 to 2023
$75.0M
World Reference Center for Emerging Viruses and Arboviruses (WRCEVA)R24AI120942 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI WEAVER, SCOTT C · 2016 to 2024
$8.5M
Biodefense Training ProgramT32AI060549 · NIAID · UNIVERSITY OF TEXAS MEDICAL BR GALVESTON · PI ASHOK K CHOPRA, Janice J Endsley · 2004 to 2026
$3.0M
Identifying host and viral correlates for coronavirus pathogenesisR01AI153602 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI JOHNSON, BRYAN A · 2020 to 2023
$2.0M
The Host Genetics of Age-Dependent SusceptibilityR21AI145400 · NIAID · UNIVERSITY OF TEXAS MED BR GALVESTON · PI MENACHERY, VINEET D · 2020 to 2021
$451k
NIAID NIH HHS R01 AI153602NIAID NIH HHS R21 AI145400NIAID NIH HHS R24 AI120942NIAID NIH HHS T32 AI060549NIAID NIH HHS U19 AI171413
6 · The paper itself

Abstract

Viruses interact with numerous host factors to facilitate viral replication and to dampen antiviral defense mechanisms. We currently have a limited mechanistic understanding of how SARS-CoV-2 binds host factors and the functional role of these interactions. Here, we uncover a novel interaction between the viral NSP3 protein and the fragile X mental retardation proteins (FMRPs: FMR1, FXR1-2). SARS-CoV-2 NSP3 mutant viruses preventing FMRP binding have attenuated replication in vitro and reduced levels of viral antigen in lungs during the early stages of infection. We show that a unique peptide motif in NSP3 binds directly to the two central KH domains of FMRPs and that this interaction is disrupted by the I304N mutation found in a patient with fragile X syndrome. NSP3 binding to FMRPs disrupts their interaction with the stress granule component UBAP2L through direct competition with a peptide motif in UBAP2L to prevent FMRP incorporation into stress granules. Collectively, our results provide novel insight into how SARS-CoV-2 hijacks host cell proteins and provides molecular insight into the possible underlying molecular defects in fragile X syndrome.

Indexed as

COVID-19Fragile X SyndromeFragile X Messenger Ribonucleoprotein 1HumansPeptidesRNA-Binding ProteinsSARS-CoV-2FMR1 protein, humanFragile X Messenger Ribonucleoprotein 1FXR1 protein, humanPeptidesRNA-Binding ProteinsFragile X SyndromeNSP3SARS-CoV-2Stress GranulesUBAP2L

Identifiers

PMID38177924
PMCPMC10897489
OpenAlexW4390528146

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.